bioAffinity Technologies Reports Strong Q1 2025 Growth

bioAffinity Technologies, Inc. ( (BIAF) ) has released its Q1 earnings. Here is a breakdown of the information bioAffinity Technologies, Inc. presented to its investors.

bioAffinity Technologies, Inc. is a biotechnology company specializing in noninvasive diagnostic tests for early-stage lung cancer and other lung diseases, with its flagship product being the CyPath® Lung test. In the first quarter of 2025, bioAffinity Technologies reported a significant increase in revenue, driven by a 276% year-over-year surge in CyPath® Lung sales. The company also announced strategic cost-reduction measures and improvements in test processing efficiency, which are expected to enhance profitability and expand their market reach. Key financial metrics for the quarter included $1.9 million in revenue and a net loss of $2.7 million, with operating expenses slightly increasing due to higher administrative and sales costs. Looking ahead, bioAffinity Technologies aims to continue expanding the availability of CyPath® Lung and developing new diagnostics for other lung diseases, positioning itself for future growth in the biotechnology sector.